Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Kristyn Y. DiSogra"'
Autor:
Aleksander L. Chojecki, Kristyn Y. DiSogra, Justin Arnall, Nicole Cowgill, Amy Soni, Charles H. Packman, Srinivasa Reddy Sanikommu, Nilay A. Shah, Brittany K. Ragon, Thomas G. Knight, Jing Ai, Belinda R. Avalos, Edward A. Copelan, Michael R. Grunwald
Publikováno v:
Leukemia & Lymphoma. 63:1515-1517
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc40ab107f6774b022f9671ebced6f5f
https://doi.org/10.1080/10428194.2022.2032037
https://doi.org/10.1080/10428194.2022.2032037
Autor:
Jing Ai, Brittany K. Ragon, Srinivasa R. Sanikommu, Michael R. Grunwald, Edward A. Copelan, Kristyn Y. DiSogra, Thomas G. Knight, Nilay A. Shah, Ariel Denson, Belinda R. Avalos, Aleksander L. Chojecki, Justin Arnall
Publikováno v:
Blood. 136:14-17
Introduction Gleevec, Imatinib mesylate, is the first in class BCR-ABL tyrosine kinase inhibitor initially approved to treat CML. In February 2016, generic imatinib products became available. As generic products are not required to offer comparative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a73af1ff6eba0248f64002bfa3993fc0
https://doi.org/10.1182/blood-2020-137250
https://doi.org/10.1182/blood-2020-137250
Autor:
Aleksander L, Chojecki, Justin, Arnall, Danielle, Boselli, Rushil, Patel, Zane, Chiad, Kristyn Y, DiSogra, Allison, Karabinos, Tommy, Chen, Adilen, Cruz, Allison, Verbyla, Jing, Ai, Thomas G, Knight, Brittany K, Ragon, Nilay A, Shah, Srinivasa R, Sanikommu, James, Symanowski, Belinda R, Avalos, Edward A, Copelan, Michael R, Grunwald
Publikováno v:
Leukemia Research. 119:106904
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a2efa40498f2dc6f67abe8a31cdbbf
https://doi.org/10.1016/j.leukres.2022.106904
https://doi.org/10.1016/j.leukres.2022.106904
Autor:
Justin Arnall, Kristyn Y. DiSogra, Donald C Moore, Lauren Downing, Joseph B. Elmes, Thuy Tran
Publikováno v:
American journal of therapeutics. 28(5)
Background The thrombopoietin (TPO) agonists, eltrombopag and romiplostim, stimulate the production of platelets and offer an effective treatment option in relapsed/refractory immune thrombocytopenia (ITP). Recently published 2019 ITP guidelines reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5d35c8306a8393716ccc42fbf4bb7f
https://pubmed.ncbi.nlm.nih.gov/33491968
https://pubmed.ncbi.nlm.nih.gov/33491968
Autor:
Brittany K. Ragon, Belinda R. Avalos, Allison Karabinos, Kristyn Y. DiSogra, Jing Ai, Danielle Boselli, Edward A. Copelan, James T. Symanowski, Michael R. Grunwald, Nilay A. Shah, Aleksander L. Chojecki, Justin Arnall, Tommy Chen, Thomas G. Knight, Srinivasa R. Sanikommu
Publikováno v:
Blood. 138:1252-1252
Introduction: Treatment options for newly diagnosed patients (pts) with acute myeloid leukemia (AML) have historically been limited. The combination of a hypomethylating agent and venetoclax (HMA/Ven) has emerged as standard of care treatment for eld
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16f358ddf05b869b3431d32f0c63348c
https://doi.org/10.1182/blood-2021-149811
https://doi.org/10.1182/blood-2021-149811
Autor:
Brittany K. Ragon, Kristyn Y. DiSogra, Michael R. Grunwald, Nilay A. Shah, Thomas G. Knight, Jing Ai, Justin Arnall, Charles H. Packman, Srinivasa Reddy Sanikommu, Edward A. Copelan, Aleksander L. Chojecki, Nicole Cowgill, Belinda R. Avalos
Publikováno v:
Blood. 136:40-41
Background: MF patients (pts) can have significant disease-associated symptoms. Guidelines recommend evaluation of pts' symptom burdens and prognostic risk scores at clinic visits. The myeloproliferative neoplasm symptom assessment form total symptom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f29feba786c7235268004f8c247d57c
https://doi.org/10.1182/blood-2020-136319
https://doi.org/10.1182/blood-2020-136319
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522096744
Introduction Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase indicated for the treatment of a variety of B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::553e160129d4805a888b3d3e50488bcc
https://doi.org/10.1177/1078155220967440
https://doi.org/10.1177/1078155220967440
Autor:
Chojecki, Aleksander L.1 (AUTHOR), DiSogra, Kristyn Y.2 (AUTHOR), Arnall, Justin2 (AUTHOR), Cowgill, Nicole2 (AUTHOR), Soni, Amy1 (AUTHOR), Packman, Charles H.1 (AUTHOR), Sanikommu, Srinivasa Reddy1 (AUTHOR), Shah, Nilay A.1 (AUTHOR), Ragon, Brittany K.1 (AUTHOR), Knight, Thomas G.1 (AUTHOR), Ai, Jing1 (AUTHOR), Avalos, Belinda R.1 (AUTHOR), Copelan, Edward A.1 (AUTHOR), Grunwald, Michael R.1 (AUTHOR)
Publikováno v:
Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1515-1517. 3p.
Autor:
Arnall, Justin R., DiSogra, Kristyn Y., Downing, Lauren, Elmes, Joseph B., Tran, Thuy, Moore, Donald C.
Publikováno v:
American Journal of Therapeutics; Sep/Oct2021, Vol. 28 Issue 5, pe525-e530, 6p
Autor:
DiSogra, Kristyn Y, Tran, Thuy, Arnall, Justin R, Janes, Amanda, Moore, Donald C, Park, Steven I
Publikováno v:
Journal of Oncology Pharmacy Practice; Jul2021, Vol. 27 Issue 5, p1265-1269, 5p